Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134330 | 0.86 | PRKCI (0.52) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1761140 | 0.83 | DHODH (0.51) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4129131 | 0.82 | LMNA (0.59) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL30206090 | 0.81 | GRM5 (0.49) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL23388894 | 0.80 | DHODH (0.48) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29967939 | 0.80 | DHODH (0.48) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2037022 | 0.80 | DHODH (0.57) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4134889 | 0.79 | KDM4E (0.41) | DHODHALDH1A1MAPTKDM4E | |
| SCHEMBL7049905 | 0.79 | DHODH (0.46) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL479877 | 0.76 | DHODH (1.00) | DHODHMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858862-B1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | claimed |
| CN-101208311-B | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | claimed |
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2009-09-17 | — | — | US | claimed |
| CN-101208311-A | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| EP-1858862-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094691-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-07 | — | — | US | claimed |
| EP-1858862-B1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| CN-101208311-B | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | disclosed |
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2009-09-17 | — | — | US | disclosed |
| CN-101208311-A | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| EP-1858862-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094691-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-4628055-A | ASTHMA, BRONCHITIS, 1,5,8-AZANAPHTHYRIDINES | SCHERING CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |
| US-4596809-A | Substituted 1,8-naphthyridinones, useful as anti-allergic agents | SCHERING CORPORATION (US) | 1986-06-24 | — | — | US | disclosed |
| US-4551463-A | ANTIULCER | SCHERING CORPORATION (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0144996-A2 | Substituted spiro pyridine derivatives, pharmaceutical compositions containing them and processes for the preparation of such compounds and compositions | SCHERING CORPORATION (US) | 1985-06-19 | — | — | EP | disclosed |
| US-4492702-A | ATIALLERGENS, LUNG DISEASES | SCHERING CORPORATION (US) | 1985-01-08 | — | — | US | disclosed |
| EP-0127135-A2 | Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones | SCHERING CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0092786-A2 | 1,8-Naphthyridine and 1,5,8-azanaphthyridine derivatives | SCHERING CORPORATION (US) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | DHODH 2500/4885MEN1 1573/4885KMT2A 382/4885 |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | CNR2, CNR1, CHRNA2 | DHODH 2500/4885MEN1 1573/4885KMT2A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.